IDX102

IDX102 is a macrocyclic small molecule inhibitor of the Hepatitis C Virus (HCV) NS3/4A protease, originally developed by Idenix Pharmaceuticals. As a direct-acting antiviral (DAA), it was designed to bind to the active site of the NS3 serine protease, thereby preventing the cleavage of the viral polyprotein into essential non-structural proteins (NS4A, NS4B, NS5A, and NS5B) required for viral replication. IDX102 was part of Idenix's second-generation protease inhibitor program, which sought to achieve high potency and a favorable resistance profile against various HCV genotypes. Although it showed promise in preclinical evaluations, its development was eventually eclipsed by more advanced candidates such as IDX320. Following the acquisition of Idenix by Merck & Co. in 2014 and the rapid advancement of highly effective HCV combination therapies, the development of IDX102 was discontinued.